Skip to main content
SpringerLink
Log in

Vedolizumab cost effective for adults with moderate-to-severe Crohn's Disease

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhou T, et al. Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China. . Advances in Therapy : 5 Jun 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01806-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vedolizumab cost effective for adults with moderate-to-severe Crohn's Disease. PharmacoEcon Outcomes News 881, 33 (2021). https://doi.org/10.1007/s40274-021-7829-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7829-2

Search

Navigation